证券代码：688373 证券简称：盟科药业 公告编号：2025-032 上海盟科药业股份有限公司 根据公司经营管理和组织调整需要，根据《中华人民共和国公司法》等相 关法律法规和《上海盟科药业股份有限公司章程》的规定，经公司总经理提名， 董事会提名委员会任职资格审查，公司于2025年8月19日召开第二届董事会第十 八次会议，董事会以7票同意、0票反对、0票弃权的表决结果，审议通过了《关 于<公司高级管理人员调整>的议案》。公司董事会同意聘任徐有印先生（简历 后附）担任公司副总经理，任期自本次董事会会议审议通过之日起至公司第二 届董事会届满之日止。 特此公告。 上海盟科药业股份有限公司董事会 2025 年 8 月20 日 附件 徐有印先生简历 关于副总经理辞任及聘任副总经理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海盟科药业股份有限公司（以下简称"公司"）董事会于近日收到副总经 理赵东明先生递交的书面报告，因工作调整，赵东明先生申请辞去公司副总经 理职务。辞任后，赵东明先生将继续在公司任职直至离职手续办理完毕， ...

证券代码：688373 证券简称：盟科药业 公告编号：2025-030 上海盟科药业股份有限公司 第二届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海盟科药业股份有限公司（以下简称"公司"）第二届监事会第十三次会 议（以下简称"本次会议"）于2025年8月19日在公司会议室，通过现场表决与通 讯表决相结合的方式召开。本次会议通知及相关资料已于2025年8月9日通过邮 件送达全体监事。本次会议应出席监事3人，实际出席监事3人。本次会议由监 事会主席卢亮先生召集并主持。本次会议的召集和召开符合《中华人民共和国 公司法》（以下简称"《公司法》"）等相关法律、行政法规、规范性文件和 《上海盟科药业股份有限公司章程》（以下简称"《公司章程》"）的规定，会 议形成的决议合法、有效。 表决结果：3票同意，0票反对，0票弃权。 具体内容详见公司同日在上海证券交易所（www.sse.com.cn）披露的《上 海盟科药业股份有限公司2025年半年度报告》及《上海盟科药业股份有限公司 2 ...

[Glossary](index=5&type=section&id=Glossary) This section provides definitions for key terms used throughout the report [Company Profile and Key Financial Indicators](index=7&type=section&id=Company%20Profile%20and%20Key%20Financial%20Indicators) [Basic Company Information](index=7&type=section&id=Basic%20Company%20Information) This section details Shanghai MicuRx Pharmaceuticals' basic corporate information, including legal representative and addresses, with no changes in the reporting period - The company's legal representative is ZHENGYU YUAN, with its registered and office address located in the Shanghai Free Trade Zone[16](index=16&type=chunk) [Key Accounting Data and Financial Indicators](index=8&type=section&id=Key%20Accounting%20Data%20and%20Financial%20Indicators) In H1 2025, revenue grew 10.26% to 66.97 million CNY, driven by Contezolid sales, with net loss narrowing due to reduced expenses and improved cash flow, despite high R&D intensity Key Accounting Data for H1 2025 | Key Accounting Data | Current Reporting Period (Jan-Jun) | Prior Period | Year-on-year Change (%) | | :--- | :--- | :--- | :--- | | **Operating Revenue** | 66,969,753.09 CNY | 60,738,238.45 CNY | 10.26% | | **Net Profit Attributable to Shareholders** | -138,674,492.55 CNY | -201,304,246.81 CNY | N/A | | **Net Profit Attributable to Shareholders (Excluding Non-recurring Items)** | -143,358,346.31 CNY | -211,520,217.94 CNY | N/A | | **Net Cash Flow from Operating Activities** | -120,704,678.78 CNY | -229,023,837.10 CNY | N/A | | **Total Assets (Period-end)** | 772,902,757.53 CNY | - | -8.98% (Compared to prior year-end) | | **Net Assets Attributable to Shareholders (Period-end)** | 313,375,760.33 CNY | - | -28.61% (Compared to prior year-end) | - Operating revenue increased by **10.26%**, primarily due to increased sales of the self-developed product Contezolid Tablets[22](index=22&type=chunk) - Net loss narrowed year-on-year, mainly due to reduced selling expenses and R&D investment[22](index=22&type=chunk) - R&D investment as a percentage of operating revenue was **173.83%**, a year-on-year decrease of **99.75 percentage points**, primarily due to strict control over R&D expenditures[22](index=22&type=chunk) [Management Discussion and Analysis](index=11&type=section&id=Management%20Discussion%20and%20Analysis) [Main Business and Product Pipeline](index=11&type=section&id=Main%20Business%20and%20Product%20Pipeline) The company's core business is innovative small molecule drug R&D for infectious diseases, with Contezolid Tablets (MRX-1) sales growing 10.26% to 66.97 million CNY, while advancing pipeline products MRX-4, MRX-8, MRX-5, and expanding into oncology and nephrology - The first commercialized product, Contezolid Tablets (MRX-1), generated **66.97 million CNY** in operating revenue during the reporting period, a **10.26%** year-on-year increase[30](index=30&type=chunk) Core R&D Product Pipeline Progress | Product Code | Drug Type | Indication | Latest Progress | | :--- | :--- | :--- | :--- | | **MRX-4** | Contezolid Prodrug | Diabetic Foot Infections, Complicated Skin and Soft Tissue Infections | International multi-center Phase III clinical trials ongoing; NDA for complicated skin infections accepted | | **MRX-8** | Polymyxin Class | Multi-drug Resistant Gram-negative Bacterial Infections | US and China Phase I clinical trials completed | | **MRX-5** | Benzoxaborole Class | Non-tuberculous Mycobacterial (NTM) Infections | Australia Phase I clinical trial completed, China Phase I clinical trial ongoing, and granted FDA Orphan Drug Designation | | **ADC Pipeline** | Antibody-Drug Conjugate | Refractory Solid Tumors | First candidate drug has entered preclinical development | | **MRX-15/17** | Peptide-Drug Conjugate | Renal Cancer and Nephritis | In preclinical research stage | [Business Model](index=15&type=section&id=Business%20Model) The company's business model integrates in-house R&D with CRO outsourcing, MAH for manufacturing, a robust supplier evaluation system for procurement, and a hybrid sales approach combining an in-house team with CSO partnerships - R&D Model: Driven by in-house R&D, with non-core technical research outsourced to CRO service companies[40](index=40&type=chunk) - Production Model: Adopts the Marketing Authorization Holder (MAH) model, entrusting third parties with the production of APIs and formulations[43](index=43&type=chunk) - Sales Model: Combines an in-house commercialization team with external Contract Sales Organizations (CSOs) to accelerate hospital access and market coverage[44](index=44&type=chunk) [Industry Overview and Market Analysis](index=16&type=section&id=Industry%20Overview%20and%20Market%20Analysis) The severe global bacterial resistance crisis drives demand for new antimicrobials; the Chinese oxazolidinone market is expanding, with Contezolid Tablets' segment projected to reach 52.6% of treatment days by 2030, while MRX-8 targets the 25.5 billion CNY Gram-negative market, and MRX-5 addresses unmet NTM needs, with industry trends favoring innovative, safe, oral, and narrow-spectrum antibiotics - Global antimicrobial resistance is one of the greatest threats to global health, food security, and development, projected to cause **10 million deaths worldwide by 2050**[47](index=47&type=chunk) - The share of oxazolidinone drugs (the class to which Contezolid belongs) in China's treatment days is projected to increase from **44.8% in 2024 to 52.6% by 2030**[76](index=76&type=chunk)[77](index=77&type=chunk) - The market size for antibacterial drugs targeting multi-drug resistant Gram-negative bacterial infections in China is projected to grow from **19.9 billion CNY in 2024 to 25.5 billion CNY by 2030**[106](index=106&type=chunk)[109](index=109&type=chunk) - Industry Trends: Innovative anti-resistant bacterial drugs, emphasis on safety, oral formulations, and narrow-spectrum antibiotics are key development directions for the future antimicrobial market[125](index=125&type=chunk)[126](index=126&type=chunk)[127](index=127&type=chunk)[128](index=128&type=chunk) [Discussion and Analysis of Operations](index=38&type=section&id=Discussion%20and%20Analysis%20of%20Operations) During the reporting period, the company achieved steady operational growth, with Contezolid Tablets commercialization covering 580 hospitals and sales up 10.26%, while advancing pipeline products MRX-4, MRX-8, and MRX-5, and enhancing academic influence - Contezolid Tablets commercialization progress: Covered **580 hospitals** nationwide, achieved access and temporary procurement in **180 hospitals**, with a commercialization team of **82 people**[134](index=134&type=chunk) - Contezolid Tablets sales performance: Achieved operating revenue of **66.97 million CNY**, a year-on-year increase of **10.26%**[135](index=135&type=chunk) - R&D pipeline progress: MRX-4's NDA accepted; MRX-4 international multi-center Phase III clinical trial for diabetic foot infections enrolled **465 patients**; MRX-8 China Phase I clinical trial completed; MRX-5 China Phase I clinical trial enrolled **19 patients**[137](index=137&type=chunk)[138](index=138&type=chunk)[139](index=139&type=chunk)[140](index=140&type=chunk) [Analysis of Core Competencies](index=41&type=section&id=Analysis%20of%20Core%20Competencies) The company's core competencies include strong R&D with dual US-China centers, a differentiated product strategy for unmet needs, a professional global commercialization team, a rich R&D pipeline with three core technology platforms, and policy support for key products accelerating internationalization - The company possesses three core technologies: drug molecule design and discovery, metabolism-based drug design and optimization, and targeted therapy platform technologies (PDC and ADC)[149](index=149&type=chunk) - Core product Contezolid Tablets and its prodrug MRX-4 received **FDA Qualified Infectious Disease Product (QIDP)** and **Fast Track designations** in the US, while MRX-5 was granted **FDA Orphan Drug Designation**[147](index=147&type=chunk) R&D Investment Overview | Item | Current Period Amount | Prior Period Amount | Change (%) | | :--- | :--- | :--- | :--- | | **Expensed R&D Investment** | 116,413,285.79 CNY | 166,167,389.94 CNY | -29.94% | | **Total R&D Investment** | 116,413,285.79 CNY | 166,167,389.94 CNY | -29.94% | | **R&D Investment as % of Revenue** | 173.83% | 273.58% | -99.75 percentage points | [Risk Factors](index=45&type=section&id=Risk%20Factors) The company faces multiple risks, including ongoing losses from high R&D and commercialization costs, operational risks like clinical trial failures and reliance on a single product/supplier, governance risks due to no controlling shareholder, and financial/regulatory risks - Unprofitability Risk: The company has continuously invested heavily in R&D since its inception, has not yet achieved profitability, and has accumulated uncompensated losses[162](index=162&type=chunk) - Commercialization Risk: Short-term operating performance relies on the single product Contezolid Tablets, facing risks of market promotion falling short of expectations[167](index=167&type=chunk) - Single Supplier Risk: Commercialized products are exclusively manufactured by Zhejiang Huahai, posing a risk of insufficient drug supply[168](index=168&type=chunk) - No De Facto Controller Risk: The company's dispersed equity structure may lead to governance instability or inefficient decision-making[169](index=169&type=chunk) [Corporate Governance, Environment, and Society](index=53&type=section&id=Corporate%20Governance%2C%20Environment%2C%20and%20Society) [Changes in Directors, Supervisors, and Senior Management](index=53&type=section&id=Changes%20in%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, the company's Board Secretary changed from Mr. Li Zhile to Ms. Nie Anna, with no changes to core technical personnel - The company's Board Secretary changed from Li Zhile to Nie Anna[188](index=188&type=chunk) [Profit Distribution and Equity Incentives](index=53&type=section&id=Profit%20Distribution%20and%20Equity%20Incentives) During the reporting period, the company had no half-year profit distribution or capital reserve capitalization plans, and completed share registration for the first vesting period of the 2023 restricted stock incentive plan's initial grant - The company had no half-year profit distribution or capital reserve capitalization plans during the reporting period[190](index=190&type=chunk) - The company completed the share registration for the first vesting period of the initial grant under the 2023 Restricted Stock Incentive Plan[191](index=191&type=chunk) [Significant Matters](index=56&type=section&id=Significant%20Matters) [Major Litigation and Arbitration Matters](index=72&type=section&id=Major%20Litigation%20and%20Arbitration%20Matters) During the reporting period, the company's wholly-owned subsidiary MicuRx US filed a contract dispute lawsuit against CRO service provider Medpace, Inc., which is ongoing and has not yet gone to trial, with no significant adverse impact on operations - The company's wholly-owned subsidiary MicuRx US filed a lawsuit against CRO service provider Medpace, Inc. for contract disputes; the case has been filed but not yet heard[216](index=216&type=chunk)[217](index=217&type=chunk) [Progress of Proceeds from Fundraising](index=75&type=section&id=Progress%20of%20Proceeds%20from%20Fundraising) The company's net IPO proceeds were 960 million CNY, with 764 million CNY (79.62%) cumulatively invested by period-end in R&D, marketing, and operations, while up to 500 million CNY of idle funds are used for cash management Overall Utilization of Proceeds from Fundraising | Item | Amount (CNY) | | :--- | :--- | | **Net Proceeds from Fundraising** | 959,727,898.12 | | **Amount Invested This Year** | 72,818,353.03 | | **Cumulative Amount Invested as of Period-end** | 764,136,874.43 | | **Cumulative Investment Progress as of Period-end** | 79.62% | - The company approved using up to **500 million CNY** of temporarily idle proceeds for cash management, for a period of **12 months** from the date of Board approval[231](index=231&type=chunk) [Share Changes and Shareholder Information](index=79&type=section&id=Share%20Changes%20and%20Shareholder%20Information) [Share Change Information](index=79&type=section&id=Share%20Change%20Information) During the reporting period, the company's total share capital increased by **395,407 shares** to **655,605,491 shares** due to the vesting of restricted shares under the 2023 incentive plan - During the reporting period, the company's total share capital increased by **395,407 shares** to **655,605,491 shares** due to the implementation of the equity incentive plan[234](index=234&type=chunk)[235](index=235&type=chunk) [Shareholder Information](index=80&type=section&id=Shareholder%20Information) As of period-end, the company had **14,444 common shareholders**, with the top three holding over 10% each, indicating a dispersed equity structure with no controlling shareholder or de facto controller - As of the end of the reporting period, the company had a total of **14,444 shareholders**[237](index=237&type=chunk) Top Ten Shareholders' Shareholding | Shareholder Name | Shares Held at Period-end | Percentage (%) | | :--- | :--- | :--- | | Genie Pharma | 71,572,817 | 10.92 | | MicuRx（HK）Limited | 70,756,084 | 10.79 | | Best Idea International Limited | 68,752,718 | 10.49 | | JSR Limited | 38,579,770 | 5.88 | | GP TMT Holdings Limited | 18,371,317 | 2.80 | | Huagai Capital...Beijing Huagai Xincheng... | 16,441,633 | 2.51 | | Zhao Ji | 16,300,000 | 2.49 | | Zhao Jianping | 16,000,000 | 2.44 | | Xinyi Youmaikesi Financial Consulting Center... | 15,217,545 | 2.32 | | Zhejiang Huahai Pharmaceutical Co., Ltd. | 8,307,401 | 1.27 | [Bond-Related Information](index=84&type=section&id=Bond-Related%20Information) [Corporate Bond Information](index=84&type=section&id=Corporate%20Bond%20Information) During the reporting period, the company had no outstanding corporate bonds, enterprise bonds, non-financial enterprise debt financing instruments, or convertible corporate bonds - The company has no corporate bonds or convertible corporate bonds[246](index=246&type=chunk) [Financial Report](index=85&type=section&id=Financial%20Report) [Financial Statement Summary](index=85&type=section&id=Financial%20Statement%20Summary) As of June 30, 2025, total assets were **773 million CNY**, total liabilities **460 million CNY**, and equity **313 million CNY**; H1 2025 saw **66.97 million CNY** revenue, **139 million CNY** net loss, **-121 million CNY** operating cash flow, and **237 million CNY** cash and equivalents Consolidated Financial Statement Key Data Summary (Jan-Jun 2025) | Indicator | Amount (CNY) | | :--- | :--- | | **Balance Sheet (Period-end)** | | | Total Assets | 772,902,757.53 | | Total Liabilities | 459,526,997.20 | | Equity Attributable to Parent Company Owners | 313,375,760.33 | | **Income Statement (Reporting Period)** | | | Total Operating Revenue | 66,969,753.09 | | Total Operating Costs | 209,906,680.34 | | Net Profit | -138,674,492.55 | | **Cash Flow Statement (Reporting Period)** | | | Net Cash Flow from Operating Activities | -120,704,678.78 | | Net Cash Flow from Investing Activities | 37,538,810.77 | | Net Cash Flow from Financing Activities | 47,673,187.41 | | Cash and Cash Equivalents at Period-end | 236,905,387.67 | [Summary of Notes to Consolidated Financial Statements](index=129&type=section&id=Summary%20of%20Notes%20to%20Consolidated%20Financial%20Statements) Notes to financial statements show period-end cash of **269 million CNY**, financial assets held for trading of **253 million CNY**, and accounts receivable of **37.76 million CNY** (4% allowance); R&D expenses were **116 million CNY** (down **29.94%**); long-term borrowings totaled **136 million CNY**, and **15.26 million CNY** in share-based payment expenses were recognized - Period-end cash and cash equivalents totaled **269 million CNY**, with **97.67 million CNY** held overseas[386](index=386&type=chunk) - R&D expenses for the period amounted to **116 million CNY**, a year-on-year decrease of **29.94%**, primarily comprising outsourced R&D expenses (**82.14 million CNY**) and employee compensation (**20.32 million CNY**)[483](index=483&type=chunk) - Total share-based payment expenses recognized this period were **15.26 million CNY**, recorded under selling, general and administrative, and R&D expenses[552](index=552&type=chunk) - The company has pending litigation, with subsidiary MicuRx US suing CRO service provider Medpace for contract disputes; the case has been filed but not yet heard[553](index=553&type=chunk)[555](index=555&type=chunk)

Core Insights - The company, Amgen Pharmaceutical (688373), reported a revenue of 66.97 million yuan for the first half of 2025, reflecting a year-on-year growth of 10.26% [1] - The net profit attributable to shareholders was a loss of 139 million yuan, an improvement from a loss of 201 million yuan in the same period last year [1] - The basic earnings per share were -0.21 yuan [1] Revenue Analysis - The increase in revenue was primarily driven by the sales growth of the self-developed product, Contizolam Tablets [1] Profitability Insights - The narrowing of the net loss compared to the previous year was mainly due to a reduction in selling expenses and research and development investments [1]

盟科药业公告，2025年上半年营业收入6696.98万元，同比增长10.26%。归属于上市公司股东的净亏损 1.39亿元，上年同期净亏损2.01亿元。基本每股收益-0.21元／股，上年同期为-0.31元／股。 ...

人民财讯8月19日电，盟科药业(688373)8月19日晚间披露2025年半年报，公司上半年实现营业收入 6696.98万元，同比增长10.26%；归母净利润为-1.39亿元，去年同期亏损2.01亿元。基本每股收益-0.21 元。报告期内，营业收入同比上涨，主要系公司自研产品康替唑胺片的销量增长所致；归属于上市公司 股东的净利润亏损幅度较上年同期收窄，主要系销售费用及研发投入减少导致。 ...

最新公告显示，公司股东盟科香港计划减持不超过3%的公司股份。这一减持计划可能对市场情绪产生 一定影响。从资金流向来看，当日主力资金净流出1767.84万元，近五日累计净流出2882.71万元。 盟科药业-U股价报7.93元，较前一交易日下跌0.03元，跌幅0.38%。盘中最高触及7.96元，最低下探至 7.50元，成交量为201474手，成交金额达1.57亿元。 该公司属于生物制品行业，专注于创新药研发。作为上海板块上市公司，盟科药业-U目前总市值为 51.99亿元，流通市值为41.67亿元。 风险提示：股市有风险，投资需谨慎。本文不构成任何投资建议，投资者应自主决策并承担相应风险。 ...

Group 1 - Baiya Co., Ltd. achieved a net profit of 188 million yuan in the first half of 2025, a year-on-year increase of 4.64% [1] - The company reported an operating income of 1.764 billion yuan, up 15.12% year-on-year [1] - Basic earnings per share were 0.44 yuan [1] Group 2 - Leike Defense reported a net loss of 41.67 million yuan in the first half of 2025, compared to a loss of 66.43 million yuan in the same period last year [2] - The company achieved an operating income of 542 million yuan, a year-on-year increase of 9.77% [2] - Basic earnings per share were -0.03 yuan [2] Group 3 - Jinggong Technology achieved a net profit of 113 million yuan in the first half of 2025, a year-on-year increase of 15.55% [3] - The company reported an operating income of 1.061 billion yuan, up 10.31% year-on-year [3] - Basic earnings per share were 0.22 yuan [3] Group 4 - Yuejian Intelligent reported a net profit of 62.63 million yuan in the first half of 2025, a year-on-year increase of 46.99% [4] - The company achieved an operating income of 651 million yuan, up 13.22% year-on-year [4] - Basic earnings per share were 0.2436 yuan [4] Group 5 - Wanwei High-tech achieved a net profit of 256 million yuan in the first half of 2025, a year-on-year increase of 97.47% [6] - The company reported an operating income of 4.061 billion yuan, up 4.90% year-on-year [6] - Basic earnings per share were 0.122 yuan [6] Group 6 - Keli Equipment achieved a net profit of 82.78 million yuan in the first half of 2025, a year-on-year increase of 4.88% [7] - The company reported an operating income of 318 million yuan, up 12.41% year-on-year [7] - Basic earnings per share were 0.87 yuan [7] Group 7 - Jinwo Co., Ltd. achieved a net profit of 25.47 million yuan in the first half of 2025, a year-on-year increase of 94% [8] - The company reported an operating income of 614 million yuan, up 7.96% year-on-year [8] - Basic earnings per share were 0.21 yuan [8] Group 8 - Longyuan Technology achieved a net profit of 28.28 million yuan in the first half of 2025, a year-on-year increase of 135.6% [10] - The company reported an operating income of 362 million yuan, up 1.48% year-on-year [10] - Basic earnings per share were 0.0548 yuan [10] Group 9 - Guangting Information achieved a net profit of 42.92 million yuan in the first half of 2025, turning from loss to profit [13] - The company reported an operating income of 275 million yuan, up 26.88% year-on-year [13] - Basic earnings per share were 0.4633 yuan [13] Group 10 - Changjiang Materials achieved a net profit of 73.38 million yuan in the first half of 2025, a year-on-year increase of 5.03% [15] - The company reported an operating income of 513 million yuan, up 10.43% year-on-year [15] - Basic earnings per share were 0.5019 yuan [15] Group 11 - Yitong Century reported a net loss of 1.77 million yuan in the first half of 2025, compared to a profit of 35.87 million yuan in the same period last year [17] - The company achieved an operating income of 1.22 billion yuan, down 0.54% year-on-year [17] - Basic earnings per share were -0.0020 yuan [17] Group 12 - China Nuclear Construction signed new contracts worth 90.48 billion yuan in July 2025 [19] - The company achieved a cumulative operating income of 58.229 billion yuan [19] Group 13 - Yinlong Co., Ltd. signed a construction labor subcontracting contract worth 108 million yuan [21] - The contract is for the prefabrication of CRTSIII-type track slabs for a railway project [21] Group 14 - Xinan Century plans to apply for a comprehensive credit limit of no more than 50 million yuan from a bank [23] - The limit will be used for various business purposes including working capital loans [23] Group 15 - New Hongtai reported a net profit of 34.27 million yuan in the first half of 2025, a year-on-year decrease of 8.94% [25] - The company achieved an operating income of 308 million yuan, down 2.45% year-on-year [25] - Basic earnings per share were 0.23 yuan [25] Group 16 - Botong Co., Ltd. achieved a net profit of 13.33 million yuan in the first half of 2025, a year-on-year increase of 42.95% [26] - The company reported an operating income of 149 million yuan, up 5.23% year-on-year [26] - Basic earnings per share were 0.2135 yuan [26] Group 17 - Minfeng Special Paper reported a net profit of 15.07 million yuan in the first half of 2025, a year-on-year decrease of 68.88% [28] - The company achieved an operating income of 601 million yuan, down 23.21% year-on-year [28] - Basic earnings per share were 0.043 yuan [28] Group 18 - Changchun Yidong announced that a shareholder plans to reduce their stake by up to 2.97% [29] - The reduction period is from September 8, 2025, to December 5, 2025 [29] Group 19 - Jiukang Bio received an invention patent certificate for a reagent [30] - The patent involves the application of a specific enzyme in diagnostic reagents [30] Group 20 - Xuelang Environment announced the resignation of its general manager due to personal reasons [31] - The chairman will temporarily take over the general manager's responsibilities [31] Group 21 - Tailin Bio's subsidiary obtained a property certificate for industrial land [32] - The land area is 20,500 square meters with a usage period until July 6, 2075 [32] Group 22 - Changgao Electric New's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [33] Group 23 - Tianyoude Wine plans to use up to 147 million yuan of idle funds for cash management [34] Group 24 - Lingxiao Pump Industry used 5.9 million yuan of idle funds to purchase financial products [36] Group 25 - Mengke Pharmaceutical announced that a shareholder plans to reduce their stake by up to 3% [38] Group 26 - Kexiang Co., Ltd. plans to raise no more than 300 million yuan through a simplified procedure [40] Group 27 - Huagong Technology achieved a net profit of 911 million yuan in the first half of 2025, a year-on-year increase of 44.87% [42] - The company reported an operating income of 7.629 billion yuan, up 44.66% year-on-year [42] - Basic earnings per share were 0.91 yuan [42] Group 28 - Shanghai Jianke achieved a net profit of 23.76 million yuan in the first half of 2025, a year-on-year increase of 48.57% [43] - The company reported an operating income of 1.935 billion yuan, up 0.60% year-on-year [43] - Basic earnings per share were 0.06 yuan [43] Group 29 - Darui Electronics achieved a net profit of 132 million yuan in the first half of 2025, a year-on-year increase of 25.32% [44] - The company reported an operating income of 1.405 billion yuan, up 28.04% year-on-year [44] - Basic earnings per share were 1.00 yuan [44] Group 30 - Dongyangguang achieved a net profit of 613 million yuan in the first half of 2025, a year-on-year increase of 170.57% [45] - The company reported an operating income of 7.124 billion yuan, up 18.48% year-on-year [45] - Basic earnings per share were 0.209 yuan [45] Group 31 - Chongqing Beer reported a net profit of 865 million yuan in the first half of 2025, a year-on-year decrease of 4.03% [49] - The company achieved an operating income of 8.839 billion yuan, down 0.24% year-on-year [49] - Basic earnings per share were 1.79 yuan [49] Group 32 - Chongqing Beer announced that its subsidiary plans to increase capital by 600 million yuan [51] Group 33 - Meixin Technology announced that a shareholder plans to reduce their stake by up to 3% [53] Group 34 - Qipai Technology plans to raise no more than 159 million yuan through a private placement [55] Group 35 - Qipai Technology reported a net loss of 586.69 million yuan in the first half of 2025 [57] - The company achieved an operating income of 326 million yuan, up 4.09% year-on-year [57] - Basic earnings per share were -0.55 yuan [57] Group 36 - Huaying Technology reported a net loss of 476 million yuan in the first half of 2025 [59] - The company achieved an operating income of 721 million yuan, down 16.59% year-on-year [59] - Basic earnings per share were -0.1723 yuan [59] Group 37 - Best reported a net profit of 148 million yuan in the first half of 2025, a year-on-year increase of 3.30% [61] - The company achieved an operating income of 716 million yuan, up 2.73% year-on-year [61] - Basic earnings per share were 0.2966 yuan [61] Group 38 - Changliang Technology reported a net loss of 19.11 million yuan in the first half of 2025 [62] - The company achieved an operating income of 664 million yuan, down 5.64% year-on-year [62] - Basic earnings per share were -0.0236 yuan [62] Group 39 - Shunhao Co., Ltd. plans to use up to 35 million yuan of idle funds for entrusted wealth management [64] Group 40 - Weihede achieved a net profit of 65.97 million yuan in the first half of 2025, a year-on-year increase of 24.69% [66] - The company reported an operating income of 356 million yuan, up 38.37% year-on-year [66] - Basic earnings per share were 0.49 yuan [66] Group 41 - Huafa Co., Ltd. reported a net profit of 172 million yuan in the first half of 2025, a year-on-year decrease of 86.41% [67] - The company achieved an operating income of 38.199 billion yuan, up 53.46% year-on-year [67] - Basic earnings per share were 0.06 yuan [67] Group 42 - Mankun Technology achieved a net profit of 632 million yuan in the first half of 2025, a year-on-year increase of 62.30% [68] - The company reported an operating income of 760 million yuan, up 31.56% year-on-year [68] - Basic earnings per share were 0.43 yuan [68] Group 43 - Kelu Electronics achieved a net profit of 190 million yuan in the first half of 2025, turning from loss to profit [69] - The company reported an operating income of 2.573 billion yuan, up 34.66% year-on-year [69] - Basic earnings per share were 0.1144 yuan [69] Group 44 - Sanrenxing achieved a net profit of 144 million yuan in the first half of 2025, a year-on-year increase of 10.83% [71] - The company reported an operating income of 1.657 billion yuan, down 13.36% year-on-year [71] - Basic earnings per share were 0.68 yuan [71] Group 45 - Xinwei Communication achieved a net profit of 162 million yuan in the first half of 2025, a year-on-year decrease of 20.18% [72] - The company reported an operating income of 3.703 billion yuan, down 1.15% year-on-year [72] - Basic earnings per share were 0.1699 yuan [72] Group 46 - Yifan Pharmaceutical achieved a net profit of 304 million yuan in the first half of 2025, a year-on-year increase of 19.91% [72] - The company reported an operating income of 2.635 billion yuan, up 0.11% year-on-year [72] - Basic earnings per share were 0.25 yuan [72] Group 47 - *ST Chengchang achieved a net profit of 566 million yuan in the first half of 2025, turning from loss to profit [73] - The company reported an operating income of 201 million yuan, up 180.16% year-on-year [73] - Basic earnings per share were 0.2783 yuan [73] Group 48 - Rejing Bio announced that a controlling shareholder plans to reduce their stake by up to 1.08% [74] Group 49 - Jingu Co., Ltd. signed a strategic cooperation framework agreement with Luming Robotics [75]

根据公告，股东MicuRx(HK)Limited（以下简称"盟科香港"）计划于2025年9月5日至2025年12月4日 期间通过集中竞价交易和大宗交易方式减持其持有的公司股份合计不超过19,668,163股，减持比例不超 过公司总股本的3%。 其中以集中竞价方式减持所持股份数量不超过6,556,054股；以大宗交易方式减持所持股份数量不超 过13,112,109股。 截至公告披露日，盟科香港持有盟科药业70,756,084股，占公司股份总数的10.79%。上述股份为公 司首次公开发行并上市前取得的股份，其中26,477,060股已于2025年8月5日起上市流通。 中国经济网北京8月15日讯 盟科药业（688373.SH）昨日晚间披露《股东减持股份计划公告》。 盟科香港为直接持股5%以上股东，无一致行动人。盟科香港由MicuRx Pharmaceuticals,Inc.（以下 简称"盟科开曼"）100%持有，盟科开曼部分股份由公司外籍个人股东和员工持有，本次减持主要是为 满足外籍股东和员工个人资金需求。 今年一季报显示，盟科香港为盟科药业第2大股东。 公司董事、高级管理人员及核心技术人员Zhengyu Yuan ...

Summary of Key Points Core Viewpoint - Multiple shareholders across various companies are planning to reduce their stakes, indicating potential shifts in ownership dynamics within the market [1]. Shareholder Reductions - Zhongzi Technology: Shareholder Yin'an Lingying plans to reduce holdings by up to 3.00% [1] - Boshi Jie: Shareholders Botianyi and Huitianyi intend to reduce a combined total of up to 3% [1] - Rejing Biology: Chairman and General Manager Lin Changqing plans to reduce holdings by up to 1 million shares [1] - Meixin Technology: Shareholder Runkai Investment plans to reduce holdings by up to 3% [1] - Mengke Pharmaceutical: Shareholder Mengke Hong Kong intends to reduce holdings by up to 3% [1] - Xiangyuan New Materials: Multiple shareholders plan to reduce a total of up to 2.924% [1] - Baipusais: Shanghai Baipusais and Shanghai Baipujiale plan to reduce holdings by up to 2.74% [1] - Junshi Biological: Shareholder Shanghai Tanying plans to conduct a block trade to reduce holdings by up to 2% [1] - Hainan Huatie: Shareholder Hu Danfeng plans to reduce holdings by up to 44.2295 million shares [1] - Mailande: Chen Jiangning plans to reduce holdings by up to 259,800 shares [1] - Zhongyan Dadi: Shareholder Yishan plans to reduce holdings by up to 3.00% [1] - Tiandi Digital: Shareholder Li Zhuoya plans to reduce holdings by up to 951,800 shares [1] Other Notable Events - Aerospace Hongtu: There are overdue commercial acceptance bills totaling 16.7754 million yuan [1] - Yuguang Jinchang: The company has terminated the issuance of shares to specific objects and signed a termination agreement [1]